Biofermin Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biofermin Pharmaceutical Company Limited with three other
companies in this sector in Japan:
Wakamoto Pharmaceutical Co., Ltd.
sales of 10.83 billion Japanese Yen [US$96.50 million]
of which 52%
was Medical Pharmaceutical Products),
I'rom Group Co Ltd
(4.89 billion Japanese Yen [US$43.57 million]
of which 74%
was Smo Business), and
Koei Chemical Company, Limited
(17.28 billion Japanese Yen [US$153.95 million]
Biofermin Pharmaceutical Company Limited reported sales of ¥10.62 billion (US$94.61 million)
March of 2017.
increase of 9.9%
versus 2016, when the company's sales were ¥9.67 billion.
Despite this increase, sales are still
below the level achieved in 2015, when Biofermin Pharmaceutical Company Limited
reported sales of ¥10.85 billion.
Sales of Biofermin Tablet saw an increase
that was more than double the company's growth rate: sales were up
20.1% in 2017, from
¥1.58 billion to ¥1.90 billion.
Not all segments of Biofermin Pharmaceutical Company Limited experienced an increase in sales in 2017:
sales of Biofermin Synthetic Drugs fell 2.5% to ¥776.50 million.